TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Can Continuous Glucose Measurements Help Diabetic Patients Treated With an Implantated Pump?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 18 and 70~* Type 1 diabetes for at least 1 year~* Treatment of diabetes withimplanted insulin pump for at least 6 months~* HbA1c level between 7.5 and 10%~* Minimum of 4 capillary glucose controls per day over past 3 months~* Use of CGM at least 75% during run-in period~* Willingness to follow all study procedures~* Informed consent signed~* Patient must be affiliated or beneficiary of a social medical insurance~Exclusion Criteria:~* Pregnancy of breast feeding, or intention to be pregnant during the study duration~* Impaired cognitive or psychological abilities which may result in defective adherence to study procedures~* Any disease which could make the use glucose sensor difficult (ex : blindness, severe arthrosis or immobility)~* Known allergy to medical adhesive or glucose sensor component~* Medication affecting glucose metabolism, unless stable during the study~* Long term use of continuous glucose measurements during pas 6 months~* Pump implanted more than 6 years ago~* Anti-insulin antobodies syndrom~* Active enrollment in another clinical trial or participation in a study within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Glucose Measurement (CGM) (Type: EXPERIMENTAL): Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
- Control (Type: NO_INTERVENTION): Patients will manage their diabetes as usual as recommended by their care team.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Distal Radius Steroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intra- or extra-articular distal radius fractures (AO 23-A2,3; 23B-1,2,3; 23C-1,2,3) treated with open reduction internal fixation (ORIF)~* Age \>18~Exclusion Criteria:~* Open fractures~* Pathologic fractures~* Concomitant ipsilateral upper extremity fracture (not including distal ulna)~* Medical contraindication to systemic glucocorticoids (insulin-dependent Diabetes mellitus, history of avascular necrosis, allergy)~* Narcotic dependence~* Women who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): Test Group will receive 10mg intravenous dexamethasone at the time of incision, administered by the assigned anesthesiologist. Post-surgery, Test Group patients will be prescribed a 6-day oral methylprednisolone taper course.
- Control Group (Type: OTHER): Standard of care with no placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanism of Weight Loss After Endoscopic and Laparoscopic Sleeve Procedures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. BMI ≥ 30 Kg/m2 scheduled to undergo a bariatric intervention~2. Patients who will be undergoing ESG or LSG as part of their clinical care Age between 18 and 75 years.~3. Both male and female subjects will be included in the study.~4. Subjects from any ethnic background will be included in the study.~5. Female participants of childbearing age should not be pregnant. (Pregnancy test will be performed on all women of child bearing potential before any standard of care endoscopic procedure. For the purpose of the study we will record that information in the patient study records).~6. Successfully complete the screening process.~7. Patients able to provide written informed consent on the IRB/EC-approved informed consent form.~8. Demonstrate willingness to follow protocol requirements, including follow-up schedule, and completion of questionnaires.~9. Having standard of care therapy (endoscopic or laproscopic) for treatment of Obesity.~Exclusion Criteria:~1. Pregnant or planning to become pregnant during period of study participation.~2. Female participants who are breast-feeding.~3. Severe Immunodeficiency.~4. Severe malnutrition.~5. The participant has life expectancy of less than 1 year due to other medical conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Endoscopic Sleeve Gastrectomy (Type: None): This group includes all patient who undergo Endoscopic Sleeve Gastrectomy for weight loss
- Laproscopic Sleeve Gastrectomy (Type: None): This group includes all patient who undergo Laproscopic Sleeve Gastrectomy for weight loss

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects or their legally authorized representative must provide a signed and dated informed consent form to participate in the study.~2. Subjects must be able (in the judgment of the Investigator) to understand the nature of the study and all risks involved with participation in the study.~3. Subjects must be willing to cooperate and comply with all protocol restrictions and requirements.~4. Subjects must have successfully completed all Study MT-1186-A02 visits and have been compliant with study drug.~Exclusion Criteria:~1. Subjects of childbearing potential unwilling to use an acceptable method of contraception from the Day 1/screening visit until 3 months after the last dose of study medication. Subjects who are sexually active who do not agree to use contraception during the study period.~2. Subjects who are female, of childbearing potential, and pregnant (a positive pregnancy test) or lactating at the Day 1/screening visit.~3. Subjects who have a significant risk of suicide. Subjects with any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act, without a specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the Columbia-Suicide Severity Rating Scale (C-SSRS) at Week 48 of Study MT-1186-A02.~4. Subjects who are not eligible to continue in the study, as judged by the Investigator in conjunction with the MTDA medical monitor.~5. Subjects who are unable to take their medications orally or through a PEG/RIG tube.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MT-1186 - Group 1 (Type: EXPERIMENTAL): Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
- MT-1186 - Group 2 (Type: EXPERIMENTAL): Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Plasma Concentration of Biological Markers in Placental Abruption

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - to 45-years old, inclusive~* Suspected or confirmed PA or phenotypically matched controls~* All modes of delivery~* Gestational age greater than 28 weeks~* Singleton pregnancy~Exclusion Criteria:~* Intrauterine fetal demise,~* Severe fetal anomalies (infant not expected to survive)~* Inability to communicate in English

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placental Abruption (Type: None): Mother-infant dyads with suspected or confirmed diagnosis of placental abruption
- Phenotypically-matched controlled group (Type: None): Healthy mother-infant dyads admitted for delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: IBI188 Combination Therapy in Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with locally advanced or metastatic solid tumors cannot be cured by surgery or other local treatments .~2. Aged ≥ 18 years (≥ 12 years is acceptable in Cohort C).~3. Able to provide archived or fresh tumor tissue samples for biomarker assessment.~4. Have at least one measurable lesion according to RECIST version 1.1.~5. ECCG PS score of 0-2.~6. Adequate organ and bone marrow functions .~7. Life expectancy ≥ 12 weeks.~8. Female subjects of childbearing potential or male subjects with partners of childbearing potential should take effective contraceptive measures throughout the whole treatment period and until 6 months after treatment.~9. Must voluntarily sign the Informed Consent Form (ICF), and be able to follow all study requirements and procedures. For the subjects enrolled in Cohort C who are ≥ 12 and \< 18 years old, in addition to obtaining the child's own consent, their guardians should provide informed consent and sign the ICF.~Exclusion Criteria:~1. Previous exposure to any CD47 antibody, SIRPα antibody, CD47/SIRPα recombinant protein or other inhibitors that act in the same pathway.~2. Previous exposure to any anti-programmed death receptor 1 (PD-1) or anti-programmed death-ligand (PD-L1) antibody (except Cohort C).~3. Concurrent participation in another clinical study.~4. The last dose of anti-tumor therapy is within 4 weeks before the first dose of study treatment.~5. Have undergone major surgical procedures within 4 weeks prior to the first dose of study treatment or planned to receive major surgery during the study treatment.~6. Presence of toxicities (excluding alopecia and fatigue) induced by previous anti-tumor therapy that has not recovered to Grade 0 or 1 as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 prior to the first dose of study treatment.~7. Known hypersensitivity to IBI188 or any ingredient in the study drug product.~8. History of other primary malignancies.~9. Female subjects who are pregnant or lactating.~10. Other ineligible conditions considered by the investigator.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): None
- Cohort B (Type: EXPERIMENTAL): None
- Cohort C (Type: EXPERIMENTAL): None
- Cohort D (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Descriptive Study of Drug Compliance in Uncontrolled Hypertensive Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patient treated with diuretics and / or beta-blockers and / or calcium-blockers and / or ACE inhibitors and / or sartans~* Holter blood pressure total average of 24h greater than 135/85 mmHg or a daytime average greater than 140/90 mmHg or a nighttime average greater than 125/75 mmHg.~* informed consent given~Exclusion Criteria:~* Adults with severe hypertension (BP ≥ 180/110 mmHg) with or without organ failure requiring therapeutic adaptation~* Adults unable to comply with study procedures~* Patients who do not wish to receive generic drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cohort of uncontrolled hypertensive patients (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Evaluation of Emergent Immobilization in External Rotation in the Management of Acute Anterior Dislocations of the Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Skeletally mature patients between 18 - 35 years of age inclusive~* Patient is seen within 24 hours from time of injury.~* Sustained an acute, first-time, traumatic anterior dislocation of the shoulder as defined by;~* Mechanism of abduction, external rotation~* Sudden pain in the shoulder~* Manipulative reduction required or~* Radiograph documenting a dislocated joint~* Willing to participate in follow-up for at least 24 months.~Exclusion Criteria:~* Incompetent or unwilling to consent~* Inability or unwillingness to comply with rehabilitative protocol or required follow-up assessments.~* Previous instability of the affected shoulder~* Significant associated fracture (Exception Hill Sachs or bankart lesions)~* Concomitant ipsilateral upper extremity injuries which may affect the patient's ability to participate in, or benefit from, a rehabilitative program.~* Neurovascular compromise of the affected limb~* A medical condition making the patient unable to wear a brace or sling~* Patient is seen within 24 hours from time of injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- External Rotation Brace (Type: EXPERIMENTAL): Shoulder placed in an external rotation brace for 4 weeks
- Traditional Sling (Type: ACTIVE_COMPARATOR): Patient placed in traditional sling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: -Male or female majority between 45 and 60 years of age~* diagnosed with Lambert-Eaton Myasthenic Syndrome.~* subjects must be taking full dose of pyridostigmine~Exclusion Criteria: - does subject have a history of liver problems?~* does subject have a history of prolonged QTc syndrome (which is a condition where there is prolongation between the start of the Q wave and the end of the T wave in the heart's electrical cycle).

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 3-4 Diaminopyridine (DAP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-hypertensives (BP 120-139/80-89).~* Fitzpatrick skin types 2 and above (i.e. the ability to tan)~Exclusion Criteria:~* History of skin cancer.~* Fitzpatrick type 1 skin (always burns, never tans).~* Red hair.~* Family history of melanoma in first degree relative.~* Atypical naevus syndrome.~* Planned holiday or foreign travel during and for 4 weeks before the period of the study.~* Concurrent administration of:~  * anti-hypertensive medication,~ * photosensitising medication,~ * systemic immunosuppressive medication.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): UVA irradiation.
- Sham UVA irradiation (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are in need of a vitrectomy.~Exclusion Criteria:~* A PVD in the study eye as assessed by the investigator using ophthalmic and alternative examination techniques.~* A history of vitrectomy in the study eye.~* A media opacity that precludes quality examination of the vitreous and fundus in the study eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasmin (Type: EXPERIMENTAL): Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with lung cancer visible on CT who are scheduled to receive radiation treatment to the area of the primary tumor will be eligible for this study - Renal function tests (blood urea nitrogen \[BUN\], creatinine \[Cr\], glomerular filtration rate \[GFR\]) within 30 days of MRI with GFR \> 59 mL/min~* All patients must give written informed consent on a form that includes Health Insurance Portability and Accountability Act (HIPAA) authorization; patient therapy will not be directed by enrollment in this study; participation in this study will not preclude patient participation in additional therapy protocols; subjects will all be recruited from patients undergoing radiotherapy at one of the Virginia Commonwealth University (VCU)-affiliated radiotherapy clinics~Exclusion Criteria:~* Patients requiring continuous supplemental oxygen~* Patients with metal implants including pace makers and defibrillators~* Patients with cerebral aneurysm clips or middle ear implant~* Patients with pain pump, a programmable shunt, or non-surgical metal (i.e. a foreign body)~* Claustrophobic patients~* Prior radiotherapy to body area under investigation~* No vulnerable populations will be enrolled (prisoners, children, pregnant females, or institutionalized individuals); women of childbearing potential will undergo a pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI, CBCT, FBCT (Type: None): Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed c-MET pathway dysregulation.~* Advanced hepatocellular carcinoma which could not be suitable for treatment with locoregional therapies or has progressed following locoregional therapy.~* Measurable disease as determined by RECIST version 1.1.~* Current cirrhotic status of Child-Pugh class A with no encephalopathy.~* Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2.~Exclusion Criteria:~* Received any prior systemic chemotherapy or molecular-targeted therapy for hepatocellular carcinoma such as sorafenib.~* Previous treatment with c-MET inhibitor or hepatocyte growth factor targeting therapy.~* Previous local therapy completed less than 4 weeks prior to dosing and, if present, any acute toxicity \> grade 1.~* Known active bleeding (e.g. bleeding from gastro-intestinal ulcers or esophageal varices) within 2 months prior to screening or with history or evidence of inherited bleeding diathesis or coagulopathy.~* Clinically significant venous or arterial thrombotic disease within past 6 months.~* History of acute or chronic pancreatitis, surgery of pancreas or any risk factors that may increase risk of pancreatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 (Type: EXPERIMENTAL): The protocol consisted of two independent parts (Dose-Determining Part and Dose Expansion Part). Patients were treated with INC280 300 mg twice a day in the Dose-Determining Part. The dose for the Expansion Part could be lower, equal or higher than in the Dose-Determining Part and was determined after the Dose Determining Part at the dose decision analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues